MEHA

Functional Brands is a sub-scale nutraceutical maker (Kirkman division) whose common stock trades at $0.01 for a ~$106K market cap — a quote that already tells you the market treats the equity as nearly worthless, and the filing explains why. The auditor has expressed substantial doubt about the company's ability to continue as a going concern, citing 'recurring losses, negative cash flows and accumulated deficit.' The numbers confirm it: revenue is effectively flat (+0.7% to $6.61M), gross margin slipped to 52.7%, and operating income swung to -$1.40M (down 510% YoY) while operating cash flow was -$1.27M. The headline $758K net income and 49% ROE are mirages — they sit on top of a $1.40M operating loss, so the profit is coming from below the operating line (non-operating/one-time items), not from the actual business.

The capital structure is the disqualifier. In late 2025 the company sold 100,000 Series A convertible preferred shares (stated value $10M) for $8M gross, plus 80,000 Series B (stated value $8M) as a bonus — roughly $18M of convertible preferred sitting ahead of a common float worth about $106K. That preferred is both a liquidation claim that swamps the $1.54M of book equity and a convertible dilution machine aimed straight at common holders. Management states plainly it 'will need additional financing in the future,' which 'may not be available when needed or may be costly and dilutive.' Negative working capital ($5.19M current assets vs. $5.75M current liabilities) and 4.91x liabilities/equity leave no cushion to avoid that dilution.